Other Corporate Information

iZafe Group resolves on a directed share issue of approximately SEK 10 million

iZafe Group AB (publ) ("iZafe" or the "Company") announces today that the Board of Directors has resolved, based on the authorization granted by the Annual General Meeting on May 28, 2025, on a directed share issue of 43,478,261 Class B shares at a subscription price of SEK 0.23 per share, with deviation from the shareholders' preferential rights (the "Directed Share Issue"), to external investors as well as a number of existing shareholders. The subscription price corresponds to a discount of approximately 11.5 percent compared to the closing price on Nasdaq First North Growth Market on June 26, 2025. Through the Directed Share Issue, iZafe will receive gross proceeds of approximately SEK 10 million before issue-related costs.

“Over the past six months, we have taken important steps that strengthen our market position – with clear growth in both Sweden and the Netherlands as well as strong demand from additional markets. At the same time, we are seeing a multiplied revenue and a steady increase in active units. By now raising new capital from both long-term shareholders and new investors, we ensure that we can continue to develop the business at a high pace and deliver according to the plan we have clearly communicated. This share issue is a sign of strength and a result of the trust that has been built – not only in our product portfolio, but also in the team, our strategy, and the market potential ahead. We are convinced that this step benefits all shareholders and lays the foundation for continued growth and value creation,” comments Anders Segerström, CEO of iZafe Group AB.

The Directed Share Issue
The Directed Share Issue comprises 43,478,261 Class B shares and has been resolved by the Board of Directors based on the authorization granted by the Annual General Meeting held on May 28, 2025. The right to subscribe for shares in the Directed Share Issue is granted to external investors and a number of existing shareholders. The subscription price is SEK 0.23 per share, representing a discount of approximately 11.5 percent compared to the closing price on Nasdaq First North Growth Market on June 26, 2025. The subscription price has been determined through arm’s length negotiations with external investors in the Directed Share Issue, in consultation with the Company’s financial advisor Stockholm Corporate Finance AB, and based on an analysis of several market factors. The Directed Share Issue also enables the Company to capitalize on the current interest in the Company’s shares among the subscribers at a price in line with the prevailing market price. The Board of Directors therefore assesses that the subscription price has been determined on market terms considering current market conditions. Through the Directed Share Issue, the Company will receive approximately SEK 10 million before transaction-related costs, which are estimated to amount to approximately SEK 0.29 million. The subscribers in the Directed Share Issue include both existing long-term shareholders of the Company – Eva Redhe, Gästrike Nord Invest AB, Stefan Wård, Filippa Landström, Junior Farma S.L. and Massimiliano Franzé – and new shareholders Erik Dahlberg, Rustan Panday, and Olle Olsson.

Background and Rationale for the Directed Share Issue
The purpose of the Directed Share Issue is to finance accelerating growth, execute strategic investments, and strengthen liquidity to enable repayment of an existing loan including interest, amounting to SEK 5.7 million, from Exelity AB. The remaining capital, approximately SEK 4.3 million before issue-related costs, strengthens iZafe’s working capital and ensures greater capacity to meet the clearly increasing demand for Dosell in existing and new markets.

Deviation from the Shareholders’ Preferential Rights
The purpose of the Directed Share Issue and the reason for the deviation from the shareholders’ preferential rights is to carry out a capital raise in a time- and cost-efficient manner. The Board has evaluated the possibility of primarily conducting a rights issue. The Company has weighed the advantages and disadvantages of a rights issue compared to a directed share issue and concluded that a rights issue (i) would be significantly more time-consuming and may risk the Company missing potential growth opportunities, (ii) would result in considerably higher issue-related costs, primarily due to the procurement of a guarantee consortium and legal fees, (iii) would expose the Company to greater market volatility, and (iv) would likely need to be conducted at a lower subscription price and result in higher dilution, which would disadvantage all shareholders. In addition, a rights issue would not provide the Company with capital in time to repay short-term debt financing, thus impairing the ability to meet such obligations. The Directed Share Issue also allows the Company to take advantage of current investor interest in its shares at a price aligned with the prevailing market price. Given the above and after careful consideration, the Board assesses that the Directed Share Issue is the most favorable financing option for iZafe and in the best interest of both the Company and its shareholders, and therefore also justifies a deviation from the main rule of shareholders’ preferential rights. The subscription price in the Directed Share Issue has been determined through arm’s length negotiations with the new external investors, based on the prevailing share price of the Company’s Class B shares. Furthermore, the Board has ensured the market-based nature of the subscription price in consultation with financial advisors, based on current market conditions and previously indicated price levels in discussions with potential investors. In the Board’s assessment, the market terms of the price have thus been confirmed through this process. The reason for including existing shareholders in the Directed Share Issue is partly that this was part of the negotiation with the new external investors, and partly because the Board deemed it strategically wise to include these long-term and committed shareholders in the Directed Share Issue – to help strengthen the credibility and trust in the Company on the market, for the benefit of all shareholders.

Number of Shares, Share Capital, and Dilution
Through the Directed Share Issue, the Company’s share capital will increase by SEK 2,173,913.05, from SEK 16,086,808.55 to SEK 18,260,721.60, through the issuance of 43,478,261 Class B shares. This means that the total number of shares will increase from 321,736,171 to 365,214,432 shares, of which 600,000 are Class A shares carrying ten (10) votes per share at the general meeting, and 364,614,432 are Class B shares carrying one (1) vote per share. The Directed Share Issue entails a dilution of approximately 11.9 percent of the share capital for existing shareholders, calculated as the number of Class B shares issued in the Directed Share Issue divided by the total number of shares in the Company after the share issue.

Advisors
Stockholm Corporate Finance is acting as financial advisor and LW Advisory as legal advisor to iZafe in connection with the Directed Share Issue. Aqurat Fondkommission is acting as issuing agent in connection with the Directed Share Issue.

Important Information
The publication, release, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in jurisdictions where this press release has been published or distributed must inform themselves of and comply with such legal restrictions. Recipients of this press release are responsible for using it and the information contained herein in accordance with applicable rules in their respective jurisdictions. This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction where such offer or solicitation would be unlawful or would require additional registration or other measures.

This press release does not constitute an offer to buy or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration under, or an exemption from, the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus, or any other jurisdiction where such announcement, publication, or distribution would be contrary to applicable regulations or would require additional registration or other measures than those required under Swedish law. Any failure to comply with this instruction may constitute a violation of the Securities Act or applicable securities laws in other jurisdictions.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not approved any offer to the public of securities in any EEA member state and no prospectus has been or will be prepared in connection with the Directed Share Issue. In each EEA member state, this communication is only addressed to “qualified investors” in that member state as defined in the Prospectus Regulation.

This press release does not identify or purport to identify the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to acquire or subscribe for new shares in the Directed Share Issue must be made solely based on publicly available information, which has not been independently verified by the financial advisor.

This press release does not constitute a recommendation concerning any investor’s decision regarding the Directed Share Issue. Each investor or potential investor should conduct their own investigation, analysis, and evaluation of the business and information described in this press release and all publicly available information. The price and value of securities can decrease as well as increase. Past performance is not an indication of future performance. Neither the content of the Company’s website nor any other website accessible through hyperlinks on the Company’s website is incorporated into or forms part of this press release.

Failure to comply with these instructions may constitute a violation of the Securities Act or applicable laws in other jurisdictions.

Forward-looking Statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations regarding and targets for the Company’s future operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies, and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by words such as “believe,” “expect,” “anticipate,” “intend,” “may,” “plan,” “estimate,” “will,” “should,” “could,” “aim” or “might,” or, in each case, their negative or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which in turn are based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those described in the forward-looking statements. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements in this press release. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are error-free and accepts no responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. The information, opinions, and forward-looking statements contained in this press release speak only as of its date and may be subject to change without notice. The Company undertakes no obligation to review, update, confirm, or release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com

iZafe Group resolves on a directed share issue of approximately SEK 10 million

Affärer Partners

Monthly Update May – Surpassing 1,000 Units and Growing Strategic Partnerships

May has been an eventful month where we took yet another important step forward. The number of active billable Dosell units increased by an additional 14% from April – a growth now built on an ever-larger base volume. At the same time, we passed a major symbolic milestone: more than 1,000 active units in operation, showing that we’ve made it through the most challenging phase – building a stable, scalable, and in-demand solution.

Growth is driven both by more municipalities and partners starting to use Dosell – and by existing customers prescribing more units per client. We are seeing broad and growing traction, even though we’re still coming from relatively modest volumes. That makes the strength of our growth rate all the more encouraging.

We are now entering the summer months, which traditionally means a somewhat slower pace due to holidays. But we look forward to ramping up again in the fall – firmly anchored in our long-term strategy.

Sweden: Growth in VGR and Increasing Demand Ahead of Autumn
In May, two more municipalities in the Västra Götaland region (VGR) began using Dosell, bringing our presence in the region to 14 municipalities. Several of these have started increasing their internal volumes and are receiving very positive feedback from both staff and users.

Two new municipalities have approved pilot projects with Dosell set to start right after summer. We’ve also held numerous presentations for municipalities now considering launching their own pilots – a clear sign of the strong momentum we’re experiencing in the Swedish public care sector.

At Vitalis, the Nordic region’s leading event for health and social care, we gained strategic traction – both through our presence and by presenting collaborations with Tamro, JDM Innovation, and Phoenix Group. The reaction from visitors was overwhelmingly positive, summarized best by the comment: “Finally, two solutions in one system!”

Especially appreciated was our joint stage appearance with ATEA and Ulricehamn Municipality, where Ulricehamn shared their successful implementation and how their “slow and steady” approach has led to stable, positive development. Many home care teams in the municipality are now reaching out, eager to start using Dosell themselves.

We also participated in Senior Day in Kungsträdgården, where we received great interest in our consumer solution. At the same time, our partner Zafe exhibited at the Dementia Days event, where Dosell attracted significant attention for its value in early intervention for cognitive impairment. The new Social Services Act emphasizes this very need – and many now see Dosell as a key part of the solution.

Spain: Pharmacy Network and Interest from Private Care Providers
In Spain, our partner Ti Medi continues rolling out Dosell through the national pharmacy network, which includes over 1,500 pharmacies.

Following strong media attention in April, private care providers have also started to show interest in Dosell. Our B2B solution is now being actively presented to these providers, who see the opportunity to complement their existing care structures with a digital solution that enhances independence and safety in medication management.

The Netherlands: Continued Growth and Trade Fair Momentum
In the Netherlands, growth continues at a rapid pace. Our customer TCCN is highly engaged and has established an efficient approach for broad outreach – already leading to concrete meetings with new stakeholders. At the same time, their existing customers are increasing their volumes month over month.

Dosell TV has generated strong interest, and our presence at the April trade fair served as a clear catalyst for new contacts. Several of these are now in the quotation or implementation phase. The combination of proactive sales, a strong network, and a value-driven offering that meets real needs gives us excellent conditions for continued expansion together with TCCN.

Strategic Partnership – LOI with JDM Innovation
In May, we signed a Letter of Intent with JDM Innovation, aiming to establish a strategic partnership in Europe. JDM is a well-established player in logistics, automation, and medical technology, working with both international pharmaceutical companies and pharmacy chains.

The partnership creates opportunities to integrate our technologies and opens doors to new markets in Europe. Discussions around joint pilots are already underway, and we see great potential in driving efficiency and safe medication management together in new markets.

Celebrate the 1,000-Unit Milestone with Us – Investor Evening June 12
To mark our achievement of surpassing 1,000 active units, we’re inviting you to an investor evening in Stockholm – on Thursday, June 12.

We sincerely hope as many shareholders as possible will take this opportunity to come, meet our team in person, ask questions, and get deeper insight into our journey and future vision. It’s a great chance to connect – and to experience Dosell live.

Welcome – we look forward to seeing you! Register here: https://forms.office.com/e/8qHzwLu5S8

Thank You for Your Trust – Together We Are Shaping the Future of Medication Management
iZafe Group is in a phase of strong commercial momentum. May’s results confirm both the direction and pace of our progress. We’re strengthening our partnerships, expanding our network, and building on a model that has now proven both scalable and effective.

Thank you for following our journey – and we warmly welcome you to the investor evening on Thursday, June 12.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Monthly Update May – Surpassing 1,000 Units and Growing Strategic Partnerships

Business Partners 6

Dosell Reaches 1,000 Units in Operation – Celebrates Milestone with Investor Event in Stockholm

iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that its subsidiary Dosell has reached a significant milestone: more than 1,000 active Dosell units are now in use across Europe. This marks a clear breakthrough for safe and digital medication management in the home.

To celebrate this achievement, the company invites shareholders, partners, healthcare professionals and other stakeholders to an exclusive event at its Stockholm office on June 12.

“This milestone is both personal and strategic. Reaching 1,000 Dosell units in operation proves that we’ve made it through the most challenging phase – building a stable, scalable and in-demand solution. Now we’re ready to grow in earnest. None of this would have been possible without the tremendous dedication of our team, our partners, and our shareholders who believed in us every step of the way. I look forward to sharing the next chapter with you,” says Anders Segerström, CEO of iZafe Group.

During the evening, we will share the journey toward reaching 1,000 active Dosell units – the challenges we’ve faced, the key turning points, and why this moment represents a breakthrough for both our company and the digital healthcare sector.

You’ll also get a glimpse of what’s coming next – our strategic goals, technical roadmap, and how we plan to scale up the business both in Sweden and internationally.

Food and drinks will be served in a relaxed setting where you’ll have the opportunity to connect with the Dosell team, fellow shareholders, healthcare innovators, and industry professionals.

Event Details:

Date: Wednesday, June 12
Time: From 6:00 PM
Location: iZafe Group HQ, David Bagares Gata 3A, Stockholm
Registration: https://forms.office.com/e/8qHzwLu5S8

Please note that registration is required and space is limited – spots will be allocated on a first-come, first-served basis.

About Dosell
Dosell is a medical technology solution that ensures the right person takes the right medication at the right time. The product is specifically designed to prevent double dosing and improve adherence – one of the greatest challenges in modern healthcare. Dosell is currently used by municipalities, private care providers and partners across Europe.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Dosell Reaches 1,000 Units in Operation – Celebrates Milestone with Investor Event in Stockholm

Dosell 1000

iZafe signs Letter of Intent with JDM Innovation with the goal to initiate a strategic partnership in Europe

iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that it has signed a Letter of Intent (LOI) with German company JDM Innovation GmbH, part of the PHOENIX group. The goal is to initiate a strategic partnership where the Dosell medication robot will be integrated with JDM’s dispensing solution Smila into a joint digital platform for home-based medication management. The solution is aimed at municipalities and care providers across Europe and is designed to simplify implementation, increase adherence, and free up valuable time in healthcare delivery.

JDM has more than 40 years of experience in digital healthcare solutions and is the developer of Smila – an automatic medication dispenser already in use in Finland and Denmark. In Sweden, Smila is being introduced in collaboration with Tamro AB. The PHOENIX group, to which both JDM and Tamro belong, is the European leader in pharmaceutical wholesale, pharmacy retail, and services for the pharmaceutical industry with operations in 29 healthcare markets, providing a strong foundation for European expansion.

Dosell, developed by iZafe, is a Swedish medication robot used in elder care to ensure safe and accurate medication intake at home. The solution is currently established in a growing number of municipalities in Sweden and care organizations in the Netherlands and Spain, with increasing interest from other European markets. The technology has proven to reduce medication errors, enhance patient safety, and save valuable time for healthcare staff – making it possible to deliver high-quality care to more individuals.

Through this partnership, two complementary solutions are brought together in one integrated platform. Municipalities and care providers gain access to a unified system where a single training and technical integration unlock two proven technologies – streamlining procurement, implementation, and day-to-day use.

“This is an important strategic step for iZafe. By combining our solution with Smila and leveraging PHOENIX group’s strong presence in Europe, we are creating new opportunities for growth. Together, we are making it easier for municipalities and care providers to deliver safe and effective medication management to more users,” says Anders Segerström, CEO of iZafe Group.

Both iZafe and JDM advocate that different users have different needs. With this new platform, municipalities can easily offer tailored solutions based on each user’s abilities – without compromising on safety or ease of use. The platform ensures smooth implementation and effective daily operations, helping staff save time and enabling more people to receive high-quality care.

“Dosell is a perfect complement to Smila. Together, we can offer a strong end-to-end solution on one platform that simplifies the implementation of digital medication management for municipalities across Europe,” says Martin Lafleur, CEO of JDM Innovation GmbH.

This week, Dosell will exhibit together with Tamro at Vitalis – the Nordic region’s leading event for the future of health, care, and welfare technology. The collaboration will be presented under the joint message: “Two brands. One vision. One platform.”

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe signs Letter of Intent with JDM Innovation with the goal to initiate a strategic partnership in Europe

JDM Smila Dosell

April Monthly Report – Continued Growth as We Approach 1,000 Active Units

April was a month marked by concrete expansion, deepened customer relationships, and sustained strong interest from new stakeholders. After a 12% increase in billable Dosell units in March, we grew by an additional 19% in April. This is a clear sign that our strategy is effective and that the need for digital medication management continues to rise. As it stands, we expect to reach an important milestone in May – 1,000 active billable units. This is a symbolically strong threshold that reflects both our momentum and that we are now truly beginning to scale.

Dosell continues to earn trust – both as a practical everyday tool and as a key enabler in the transition to future-oriented healthcare. Our momentum remains strong, and the interest from new municipalities and partners shows that the market is moving.

Sweden: Broad Implementation in VGR and Strong Demand
In April, two additional municipalities in the Västra Götaland Region (VGR) launched Dosell. In total, 12 municipalities in the region are now operational, and we’re seeing most of them move from pilot projects into broad implementation. This, in turn, has encouraged other municipalities – previously hesitant – to reach out and express interest in introducing Dosell.

We also conducted 10 demonstrations for municipalities currently evaluating pilot projects. One municipality launched a pilot in April, and the results so far have been very positive – no alerts have been triggered, and users report high satisfaction.

In addition, we are now engaged in exciting conversations with new potential partners who are highly interested in Dosell and its user-friendly design. We are in a phase where more stakeholders are recognizing both the need for and the potential of a solution that simplifies care, reduces strain, and empowers users.

We also participated in Seniors’ Day on May 6 in Stockholm’s Kungsträdgården – a gathering for over 60,000 seniors. We presented both Dosell and our consumer version and were met with strong interest from the target audience.
The overall development in Sweden demonstrates that our solution has gained a firm foothold and continues to grow organically through strong results and word-of-mouth.

The Netherlands: 21% Growth and New Clients from the Expo
In the Netherlands, our partner TCCN continues to deliver strong results. The number of active Dosell units increased by 21% from March to April, and the customer base is expanding.

Following the April expo, around 25 new leads were generated, leading to four meetings and one official offer. The first broadcast of Dosell TV also sparked significant interest, providing more organizations with insight into how Dosell works in practice.

The combination of satisfied end-users, innovative outreach, and a growing partner network provides a solid foundation for continued growth through the spring.

Spain: Market Launch and National TV Exposure
In Spain, Dosell has now entered the market through our partner Ti Medi and the Savioo Home concept. After participating in expos in Barcelona and France, we are now seeing increasing media coverage.

On April 26, Dosell appeared on Spanish national television in the program Aruser on La Sexta – one of the country’s largest TV channels. Host Alfonso Arús and his panel expressed strong support for the Savioo concept and emphasized the solution’s value for elderly individuals and those with complex medication routines. This provides clear proof that Dosell is gaining attention and credibility among the general public.

Over 50 pharmacies have shown interest in offering Savioo Home, which is now being launched nationally. We hope to see a tangible increase in sales in the coming months.

Dosell’s visibility in Spain strengthens our brand in a strategically important market and sets the stage for future volume growth.

To Our Shareholders – A Solid Foundation for Growth
iZafe Group remains in a development phase – but April clearly demonstrates that our strategy is bearing fruit. We are strengthening our position in Sweden through expanded cooperation in VGR, deepening our presence in Europe through new client relationships in the Netherlands, and reaching the general public in Spain through national TV.

At the same time, we are continuously engaging in new partnership discussions, and we see more readiness than ever to take action. The demand for safe, efficient medication management is growing rapidly – and Dosell is well positioned to meet that challenge.

Thank you for your continued trust and for following our journey forward.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is Carnegie Investment Bank AB (publ). Further information is available at www.izafegroup.com

April Monthly Report – Continued Growth as We Approach 1,000 Active Units

Pic News

March Monthly Update – Continued Growth and Important Progress

After an increase of billable Dosell units by 25% in January and an additional 9% in February, the number rose by another 12% in March. This is a clear indication that our strategy is working and that demand for our solution continues to grow.

At the same time, it’s important to emphasize that we are still in an early stage. Growth is occurring from relatively low levels, but the pace is exceptional. During the first quarter of 2025, we activated as many units delivering medication daily as we had over the entire first five years since the original version of Dosell was developed – a significant milestone.

Our business model now shows clear scalability, with more active Dosell units generating a growing stream of recurring revenue. We are entering a commercial breakthrough phase with record-high momentum, fueled by demand from both municipalities and international partners.

Sweden: More municipalities onboard – focus on long-term expansion
In March, three new municipalities began using Dosell. We also signed a direct procurement agreement with a municipality that, after completing a pilot, decided to fully transition to Dosell from a previously used solution. They highlight its simplicity, reliability, and the fact that doses are not locked if missed – giving both users greater independence and care services increased flexibility in scheduling.

Another municipality has launched a pilot under our structured “municipal package,” and we have several ongoing tenders within home care and LSS (disability services). Every week, we receive new inquiries – a clear signal of a shifting market where scalable, modern solutions are increasingly in demand.

At the same time, it is important to point out that volumes per municipality are still relatively low. Our focus moving forward is to support each municipality in identifying more users, increasing usage, and maximizing societal benefit. As the population ages, care must scale – and with digital tools like Dosell, we can ensure safe and high-quality care for more people without overburdening resources.

The Netherlands: Strong customer onboarding and launch of Dosell TV
In the Netherlands, we continue to meet our growth forecast. Our partner TCCN reports that their largest customer, MobileCare, delivered an additional 72 units in March. Interest is growing steadily, with more organizations joining the system each week.

In April, TCCN is launching the first broadcast of Dosell TV – a new platform to share knowledge, inspire, and support new organizations in getting started. It is a concrete step towards scaling implementation and building a vibrant user and partner community. In parallel, TCCN is also exhibiting Dosell at a major trade fair in the Netherlands in April – a key opportunity to reach new customers and further strengthen our market position.

Spain: Pharmacy network and strong role in Savioo Home
The launch of Dosell in Spain through the Savioo Home concept is now underway. Our partner has attended several trade fairs in Barcelona and France, where Dosell was presented as a central component for ensuring proper medication adherence at home.

Over 50 pharmacies have already expressed interest in adopting the concept and will soon receive promotional materials for in-store and window displays. This is only the beginning – these 50 pharmacies are the first wave in a network of 1,500 that our partner is actively working with. The ambition is high, and we see a serious, long-term effort that lays the foundation for success.

Expansion: Engaging new markets and new partners
We are currently in active discussions with new potential partners, both in existing and new geographies. Interest is coming from both public and private sectors, all recognizing the need for digital medication management. Our strategy remains clear: grow with the right partners – those with the drive and ability to scale.

To Our Shareholders – Why We Believe in Our Direction
iZafe Group is stronger than ever. We have a highly demanded solution, a growing customer network, and a proven business model. At the same time, we remain humble about the fact that we are still in a building phase – but something has clearly shifted.

We’ve set a new pace in the market, delivering more active units in one quarter than in our first five years combined – and this is just the beginning. With the momentum we’re experiencing, combined with our long-term strategy, our belief is stronger than ever: Dosell has the potential to become a cornerstone in the future of medication management.

Thank you for following our journey – and for your continued trust.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

March Monthly Update – Continued Growth and Important Progress

Mars Månadsbrev

iZafe Group AB changes Certified Adviser to Carnegie Investment Bank AB

iZafe Group AB (publ) announces today that the company is changing its Certified Adviser from Mangold Fondkommission AB to Carnegie Investment Bank AB (publ).

iZafe Group AB has entered into an agreement with Carnegie Investment Bank AB regarding the role as Certified Adviser. Carnegie Investment Bank AB will assume the role of Certified Adviser on April 1, 2025. Until then, Mangold Fondkommission AB will continue to act as the company's Certified Adviser.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group AB changes Certified Adviser to Carnegie Investment Bank AB

Affärer Partners

Increased Demand and Successful Launch – iZafe Group Strengthens Its Position

February was an intense and forward-looking month for iZafe Group. We continue to accelerate our growth and strengthen our market presence through strategic partnerships and expansion in multiple key markets. Despite seasonal variations, the number of active Dosell units increased by 9%, demonstrating continued strong demand and stable user growth. Spain successfully launched Dosell, while in Sweden, we rapidly expanded with new municipalities implementing our solution. At the same time, our establishment in the Netherlands progressed, and we look forward to further sales growth through upcoming trade fairs in both Spain and the Netherlands.

Spain: Official Launch and Initial Market Activities
After an intensive preparation phase, we have now officially launched Dosell in Spain! Spain has one of the largest healthcare markets in Europe, with over 22,000 pharmacies and an aging population driving demand for digital medication management solutions. This presents significant growth potential and an opportunity to establish Dosell as a leading solution in the market.
Our partner Ti-Medi has initiated marketing efforts by introducing the Savioo platform to all of its 1,500 pharmacies via email and through direct visits to pharmacies in multiple cities, including Barcelona, Girona, Lleida, Granollers, and Madrid. They currently produce dose sachets for 200,000 users, highlighting the significant potential for Dosell in the Spanish market.
To further strengthen our presence, we plan to gain media exposure in the near future, which will open new doors and increase awareness of Dosell in Spain. At the same time, Ti-Medi will be showcasing the Savioo concept along with Dosell at a major trade fair in Barcelona this March, providing additional visibility and opportunities to reach more industry players.

Sweden: Four New Municipalities in Operation and More on the Way
We launched Dosell in four new municipalities in February, while also conducting training sessions for two additional municipalities that plan to implement Dosell in March. Additionally, six new municipalities have expressed interest in adopting Dosell, with four of them already scheduling startup meetings in March and planning to activate their first units in April.
This represents a faster growth rate in terms of the number of municipalities than initially planned. Despite the positive development, we recognize that some challenges remain, particularly regarding the speed of implementation and initial volumes. While we have successfully introduced Dosell in multiple new municipalities in Sweden, the initial deployment is still relatively small-scale. To enhance scalability, we are focusing on improving training efforts for healthcare staff and simplifying the ordering process. However, municipalities plan to increase the number of units over time, reinforcing our strategy and our partners’ efforts to scale up Dosell’s implementation across Sweden.
Some of the feedback we have received from users and staff:

User: “I don’t have to think anymore! Finally, I get my medication at the right time, and when it lights up and beeps, I know it's time to take it.”
Healthcare Staff: “If a user hasn’t taken their medication, a simple phone call is enough to follow up—we don’t have to make a home visit.”
Healthcare Staff: “We chose Dosell as our medication dispenser because it is so simple and fits perfectly with all our municipality’s needs.”

The Netherlands: Stable Growth and Expanding Pipeline
Our market in the Netherlands continues to develop positively, with steadily increasing demand. Our partner's pipeline of new customers is growing, and we anticipate a high activation rate of Dosell units throughout the spring. Their investment in Dosell continues to yield results and is creating a stable platform for future expansion.
Additionally, our partner will be showcasing Dosell at a major trade fair in the Netherlands in April, which we believe will drive an even greater increase in sales.
We recommend following our partner’s journey in the Netherlands through their LinkedIn page, TCCN, for the latest updates and market developments.

Expansion and New Partnerships
Throughout February, we engaged in several exciting discussions with potential new partners in emerging markets. Moving forward, our strategy is to select partners with the best conditions for scaling Dosell on a larger scale. It is crucial to collaborate with organizations that understand how to implement digital technology and manage the necessary transformation processes required for successfully adopting Dosell.

We look forward to continued positive development in March and to building on the strong foundation we have established for our growth. We appreciate your engagement and look forward to sharing more progress in the upcoming updates!

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Increased Demand and Successful Launch – iZafe Group Strengthens Its Position

Apotek Dospåsar Kund

iZafe Group’s Board Member Magnus Engman Purchases 200,000 Shares

iZafe Group's board member, Magnus Engman, acquired 200,000 B-shares in the company on February 26, at a total value of 52,459 SEK (0.262 SEK per share).

The acquisition is a clear signal of Magnus long-term confidence in iZafe's strategy and future potential. His total holding now amounts to 200,000 B-shares.

"I see great potential in iZafe's continued development and want to demonstrate my commitment by investing in the company. We have a clear growth strategy, and I am convinced that we are creating long-term value for our shareholders," says Magnus Engman.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group's Board Member Magnus Engman Purchases 200,000 Shares

Magnus Engman

Launch of Dosell sales in Spain – A groundbreaking solution to improve medication adherence

iZafe Group AB ("iZafe Group") proudly announces the sales launch of Dosell in Spain through a strategic partnership with Ti-Medi, a leading player in pharmaceutical technology in Southern Europe. The launch and commercialization of Dosell, under the brand name Savioo Home, mark a significant milestone in the effort to enhance medication adherence and improve the quality of life for patients with chronic diseases.

Dosell has already established itself as an effective solution in countries such as Sweden and the Netherlands, helping users take the right medication at the right time. Through the partnership with Ti-Medi, Dosell will now be available to the Spanish market, integrating with Ti-Medi’s existing network of over 1,500 pharmacies that utilize their packaging technology for pre-dosed medications.
With Dosell, patients using Savioo Home will receive reminders to take their medication, and if they fail to do so on time, an automatic SMS alert will be sent to relatives or caregivers. This feature ensures a higher level of safety and security for both patients and their loved ones.

A Strategic Partnership for the Future
"We see tremendous potential in the Spanish market and are proud to launch Dosell through our collaboration with Ti-Medi. This is an important step in our international growth journey and our ambition to become a global leader in medication adherence," says Anders Segerström, CEO of iZafe Group.

"At Ti-Medi, we strive to provide technological solutions that simplify patients’ lives and optimize the work of healthcare professionals. Savioo Home not only automates medication management at home but also enhances security for patients, relatives, and pharmacists. This enables more precise monitoring and better adherence to treatment. We believe that the future of healthcare lies in digitalization and tools that increase safety, convenience, and trust – and Savioo Home is a major step in that direction," Says Rafa Tibau, Pharmacist and Co-founder of Ti-Medi

About Ti-Medi
Ti-Medi is a pioneer in pharmaceutical technology in Southern Europe, serving more than 1,500 pharmacies with advanced packaging and dosing solutions. The company’s mission is to enhance medication adherence and make healthcare more accessible and efficient. Read more at ti-medi.com

For more information about Savioo Home and how it can improve medication adherence and patient safety, visit the website savioo.com

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Launch of Dosell sales in Spain – A groundbreaking solution to improve medication adherence

SaviooHome